CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc)

Clinical and Experimental Medicine

Volumn 17, Issue 3, 2017, Pages 411-414

  Valentini, Gabriele ^a,b   Riccardi, Antonella ^a,b   Vettori, Serena ^a,b   Irace, Rosaria ^a,b   Iudici, Michele ^a,b   Tolone, Salvatore ^a,b   Docimo, Ludovico ^a,b   Bocchino, Marialuisa ^a,b   Sanduzzi, Alessandro ^a,b   Cozzolino, Domenico ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Systemic sclerosis; Undifferentiated connective tissue disease

Indexed keywords

CHEMOKINE; CXCL4 CHEMOKINE; UNCLASSIFIED DRUG; THROMBOCYTE FACTOR 4;

ADULT; ARTICLE; BLOOD LEVEL; CAPILLAROSCOPY; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; BLOOD; COMPLICATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROGNOSIS; SCLERODERMA, SYSTEMIC; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES;

EID: 84988637968     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-016-0437-y     Document Type: Article

References (16)

1. Avouac J, Fransen J, Walker UA, et al. EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476–81.
2. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the ‘many faces’ of systemic sclerosis. Ann Rheum Dis. 2013;72:319–21.
3. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902–12.
4. Valentini G, Marcoccia A, Cuomo G, et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibodies or capillaroscopic positivity or both. Arthritis Care Res. 2014;66:1520–7.
5. Wuttge DM, Lood C, Tufvesson E, et al. Increased serum type I interferon activity in early systemic sclerosis is associated with antibodies against Sjögren’s syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol. 2013;42:235–40.
6. Camargo CZ, Sekiyama JY, Arismendi MI, Kayser C. Microvascular abnormalities in patients with early systemic sclerosis: less severe morphological changes than in patients with definite disease. Scand J Rheumatol. 2015;44:48–55.
7. Frech TM, Murtaugh M, Gordon JK et al. Longitudinal assessment of gastrointestinal symptoms in the prospective registry of early systemic sclerosis cohort [abstract]. Arthritis Rheumatol. 2015; 67 suppl 10.
8. Valentini G. Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). Autoimmun Rev. 2015;14:210–3.
9. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370:433–43.
10. Van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative. Arthritis Rheum. 2013;65:2737–47.
11. Poormoghin H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43:444–51.
12. Valentini G, Marcoccia A, Cuomo G, et al. Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther. 2013;15:R63.
13. Aidoudi S, Bujakowska K, Kieffer N. Bikfalvi A The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS ONE. 2008;3:e2657.
14. Wiesner T, Bugl S, Mayer F, Hartmann JT, Kopp H-G. Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis. 2010;27:141–9.
15. Distler JHW, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology. 2006;45:iii26–7.
16. Volkmann ER, Tashkin DP, Roth M and Scleroderma Lung Study II Group. CXCL4 does not predict extent or progression of interstitial lung disease in systemic sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 suppl 10.